Table 2 Clinical features and outcome of the cohort
Gender | Clinical stage | Pathology | SNLG index | Smith index | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | M/F | IA | IB | IIA | IIB | IIIA | IIIB | IVA | IVB | NS | MC | <0.5 | ⩾0.5 | 0/1 | 2 | 3 | 4/5 | 5 year DSS | 5 year EFS |
(a) Classical HL | |||||||||||||||||||
<16 years | 8/4 | 1 | 1 | 5 | 0 | 1 | 1 | 0 | 3 | 1 | 11 | N/A | N/A | 4 | 3 | 4 | 1 | 100% | 90% |
⩾16 years | 19/17 | 3 | 0 | 10 | 5 | 4 | 7 | 2 | 5 | 6 | 30 | 17 | 19 | 15 | 8 | 7 | 6 | 94% | 79% |
Gender | Clinical stage | SNLG index | Smith index | ||||||||||||||||
M/F | IA | IB | IIA | IIB | IIIA | IIIB | IVA | IVB | N/A | <0.5 | ⩾0.5 | 0/1 | 2 | 3 | 4/5 | 5 year DSS | 5 year EFS | ||
(b) Lymphocyte-predominant HL | |||||||||||||||||||
6/1 | 2 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 | 6 | 1 | 0 | 0 | 86% | 67% | ||
